RBC Capital raised the firm’s price target on Bausch Health to $12 from $9 and keeps a Sector Perform rating on the shares. The firm notes that a favorable ruling in the Xifaxan patent litigation, the decison on which is highly anticipated in the coming days/weeks, would likely position the company to pursue a distribution and lead to higher share prices. RBC adds that it sees an about 76% probability that Bausch Health is able to pursue a distribution.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHC:
- Bausch Health Canada announces public drug plan listings for UCERIS
- Jefferies sees more upside for Bausch Health if Xifaxan ruling positive
- 5 Stocks Billionaire Investor Carl Icahn is Buying Now
- Salix Pharmaceuticals announces Phase 2 investigator-initiated study of RELISTOR
- Bausch Health price target raised to $7 from $6 at BofA